Literature DB >> 22711667

Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients.

Yi Yang1, Zhen Zhou, Xiao-Min Niu, Zi-Ming Li, Zhi-Wei Chen, Hong Jian, Xing-Hao Ai, Bai-Jun Cheng, Mei-Lin Liao, Shun Lu.   

Abstract

BACKGROUND AND OBJECTIVES: The objective of this study is to explore clinical risk factors for venous thromboembolism (VTE) in postoperative lung cancer patients in order to provide a basis for the prevention and treatment of postoperative VTE.
METHODS: A total of 1,001 lung cancer patients were retrospectively analyzed. Each patient was confirmed with surgical pathology diagnosis and had a complete clinical and follow-up record. VTE was identified in a combination of spiral computed tomography (CT), pulmonary angiography, and color Doppler ultrasound. We used life table method to create an occurrence frequency curve of thrombosis. We also searched for high risk factors for postoperative VTE with Cox multivariate regression model and created frequency curves of thrombosis against different risk factors using Kaplan-Meier method.
RESULTS: As of July 31, 2011, the median follow-up time is 25.73 ± 0.11 months (19.23-31.37). The cumulative frequency of VTE among 1,001 lung cancer patients is 2%, 3%, 4%, 5%, and 5.3% over 1, 3, 6, 12, and 30 months after the surgery. COX regression analysis showed that the hazard ratio of VTE occurrence in patients with incomplete resection relative to ones with complete resection is 9.867 (95% CI: 5.275-18.459, P = 0.000). And the hazard ratio of VTE occurrence is 3.472 (95% CI: 1.761-6.845, P = 0.000) in patients with anti-angiogenesis treatment compared to patients without such treatment. The hazard ratio of VTE occurrence is 2.808 (95% CI: 1.439-5.479, P = 0.002) in patients with EGFR-TKI treatment relative to patients without the treatment, and 7.520 (95% CI: 3.968-14.250, P = 0.000) in patients with an increase in D-dimer level relative to normal ones
CONCLUSIONS: The highest incidence of VTE is within 1 month after lung cancer surgery. High risk factors for VTE include incomplete surgical resection, postoperative use of anti-angiogenesis drugs, EGFR-TKI application and an increase in preoperative D-dimer level.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711667     DOI: 10.1002/jso.23190

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

1.  Post-operative hypercoagulable whole blood profiles in patients undergoing open thoracotomy vs video-assisted thoracoscopic surgery.

Authors:  Luca Spiezia; Marco Cuzzolin; Hernandez Elssy; Guido Di Gregorio; Elena Campello; Federico Rea; Andrea Zuin; Paolo Simioni
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

Review 2.  European perspectives in Thoracic Surgery, the ESTS venous thromboembolism (VTE) working group.

Authors:  Yaron Shargall; Virginia R Litle
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  The significance of perioperative coagulation and fibrinolysis related parameters after lung surgery for predicting venous thromboembolism: a prospective, single center study.

Authors:  Bo Tian; Chunfeng Song; Hui Li; Wenqian Zhang; Qirui Chen; Shuo Chen; Yili Fu; Xiaoxing Hu; Bin You; Tong Li; Bin Hu; Shengcai Hou
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study.

Authors:  Honghong Dong; Xiaoning Liang; Yingdi Gao; Yongsheng Cai; Xinyang Li; Jinbai Miao; Wenjiao Wang; Bin Hu; Hui Li
Journal:  Thorac Cancer       Date:  2022-03-22       Impact factor: 3.223

5.  The association of deep vein thrombosis with cancer treatment modality: chemotherapy or surgery?

Authors:  Mitra Samare Fekri; Mahdie Khalily Zade; Shima Fatehi
Journal:  Iran Red Crescent Med J       Date:  2014-09-05       Impact factor: 0.611

6.  The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism.

Authors:  Jing Wang; Bin Hu; Tong Li; Jinbai Miao; Wenqian Zhang; Shuo Chen; Yixin Sun; Songping Cui; Hui Li
Journal:  Ann Transl Med       Date:  2019-12

Review 7.  D-Dimer elevation and adverse outcomes.

Authors:  Rim Halaby; Christopher J Popma; Ander Cohen; Gerald Chi; Marcelo Rodrigues Zacarkim; Gonzalo Romero; Samuel Z Goldhaber; Russell Hull; Adrian Hernandez; Robert Mentz; Robert Harrington; Gregory Lip; Frank Peacock; James Welker; Ignacio Martin-Loeches; Yazan Daaboul; Serge Korjian; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

Review 8.  Venous thromboembolism and lung cancer: a review.

Authors:  Carolina Vitale; Maria D'Amato; Paolo Calabrò; Anna Agnese Stanziola; Mauro Mormile; Antonio Molino
Journal:  Multidiscip Respir Med       Date:  2015-09-15

9.  High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients.

Authors:  M Pichler; G C Hutterer; T Stojakovic; S Mannweiler; K Pummer; R Zigeuner
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

10.  Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma.

Authors:  Elsa Davidsson; Nicola Murgia; Cristian Ortiz-Villalón; Emil Wiklundh; Magnus Sköld; Karl Gustav Kölbeck; Giovanni Ferrara
Journal:  Multidiscip Respir Med       Date:  2017-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.